FQI2-34 is an orally active TFCP2 (LSF) small molecule allosteric inhibitor. FQI2-34 directly binds to the LSF protein ( K i = 63 nM), inhibits the oligomerization of LSF, efficiently suppresses the transcriptional activity of LSF ( IC₅₀ = 48 nM), and interferes with the SF-DNA interaction. FQI2-34 exhibits significant anti-proliferative activity against Huh7 cells and induces tumor regression in mouse models. FQI2-34 can be used for research on liver cancer [1].
References:
[1]. Pokharel N, et al. Preclinical Lead Optimization of Small Molecule Inhibitors of TFCP2 (LSF) for the Treatment of Liver Cancer. J Med Chem. 2026 Jan 8;69(1):574-592.
References:
[1]. Pokharel N, et al. Preclinical Lead Optimization of Small Molecule Inhibitors of TFCP2 (LSF) for the Treatment of Liver Cancer. J Med Chem. 2026 Jan 8;69(1):574-592.